Shenzhen New Industries Biomedical Engineering (300832) Fundamentals 2026 — P/E 23.5x, Revenue Analysis | SniperIQ
Shenzhen New Industries Biomedical Engineering (300832) is a CN-listed Healthcare company in Medical - Specialties with a market capitalization of ¥38.1B, trading at ¥48.43 on the SHZ. This SniperIQ fundamentals page covers Shenzhen New Industries Biomedical Engineering's valuation (P/E 23.5x, P/B 4.0x), profitability (net margin 35.5%), revenue (¥4.6B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Shenzhen New Industries Biomedical Engineering's market cap?
Shenzhen New Industries Biomedical Engineering (300832) has a market capitalization of approximately ¥38.1B, trading at ¥48.43 on the SHZ. Market cap moves with the live share price.
What is Shenzhen New Industries Biomedical Engineering's P/E ratio?
Shenzhen New Industries Biomedical Engineering's trailing twelve-month P/E ratio is 23.5x, with a price-to-book (P/B) of 4.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Shenzhen New Industries Biomedical Engineering?
Shenzhen New Industries Biomedical Engineering runs a net profit margin of 35.5%, a gross margin of 70.6%, and an operating margin of 41.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Shenzhen New Industries Biomedical Engineering generate?
Shenzhen New Industries Biomedical Engineering reported revenue of ¥4.6B for fiscal year 2025, with net income of ¥1.6B and earnings per share (EPS) of 2.06. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Shenzhen New Industries Biomedical Engineering pay a dividend?
Shenzhen New Industries Biomedical Engineering offers a trailing dividend yield of about 2.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Shenzhen New Industries Biomedical Engineering financially healthy?
Shenzhen New Industries Biomedical Engineering carries a debt-to-equity ratio of 0.00x and a current ratio of 10.54x, with a market beta of -0.21. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Shenzhen New Industries Biomedical Engineering a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Shenzhen New Industries Biomedical Engineering (300832) the key facts are: market cap ¥38.1B, P/E 23.5x, revenue ¥4.6B, 52-week range 37.5-71.51. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Shenzhen New Industries Biomedical Engineering's full fundamentals live
Get Shenzhen New Industries Biomedical Engineering's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.